Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAOUZV)

• Drug Name: Nivatrotamab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMAOUZV

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[3]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[4]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[5]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[6]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[7]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[8]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[9]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[10]
TAK-280	DM08RE5	Aggressive cancer	2A00-2F9Z	Phase 2	[11]

Drug(s) Targeting Ganglioside GD2 (GD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anti-GD2 CART	DMVQHBK	Neuroblastoma	2D11.2	Phase 2	[12]
Hu3F8 mAb	DM9MKQ5	Neuroblastoma	2D11.2	Phase 2	[13]
APN301	DMGNFBC	Neuroblastoma	2D11.2	Phase 2	[14]
4SCAR-GD2	DMEGSU5	Tumour	2A00-2F9Z	Phase 1/2	[15]
CAR-T cells targeting CD2	DMJVENR	Cervical cancer	2C77.0	Phase 1/2	[16]
CAR-T cells targeting GD2	DMFCPG0	Glioma	2A00.0	Phase 1/2	[17]
GD2-CART01	DM5VF04	Neuroblastoma	2D11.2	Phase 1/2	[18]
CAR-T cells targeting GD2	DMFCPG0	Glioma	2A00.0	Phase 1/2	[19]
IC9-GD2-CD28-OX40	DMRYHWA	Neuroblastoma	2D11.2	Phase 1	[20]
Anti-GD2 T-cells (1RG-CART)	DMBVUFL	Neuroblastoma	2D11.2	Phase 1	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ganglioside GD2 (GD2)	TT80ARU	NOUNIPROTAC	Inhibitor	[1]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [2] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [3] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [4] Clinical pipeline report, company report or official report of Genmab.
• [5] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [6] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [7] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [8] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [9] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [10] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
• [11] ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
• [12] ClinicalTrials.gov (NCT02765243) Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of Apeiron Biologics.
• [15] ClinicalTrials.gov (NCT02992210) Study on GD2 Positive Solid Tumors by 4SCAR-GD2
• [16] ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer
• [17] ClinicalTrials.gov (NCT03252171) CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
• [18] ClinicalTrials.gov (NCT03373097) Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma
• [19] ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
• [20] ClinicalTrials.gov (NCT01822652) 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
• [21] ClinicalTrials.gov (NCT02761915) A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART)